



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications
(949) 608-0841

XDx to Present at the J.P. Morgan 28th Annual Healthcare Conference

Company Also Presenting at BayBio: IMPACT 2010 Launch to Showcase Results on State of California's Life Sciences Industry Productivity and Growth Prospects

BRISBANE, CA, January 5, 2010 – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced that Pierre Cassigneul, president and chief executive officer, is scheduled to present at the J.P. Morgan 28th Annual Healthcare Conference on Wednesday, January 13, 2010 at 3:30 p.m. (PT) at the Westin St. Francis Hotel in San Francisco. This event brings together established healthcare industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers. This year more than 300 companies, both public and private, are expected to deliver presentations to over 3,500 investors.

Mr. Cassigneul will also be presenting at BayBio: IMPACT 2010 Launch on Tuesday, January 12, 2010 from 9:30 a.m. to 11:00 a.m. (PT) at the Grand Hyatt at Union Square in San Francisco. The BayBio: IMPACT report is the preeminent, in-depth report on the State of California's life sciences industry and its productivity. There are currently 233 treatments in Phase 3 clinical trials in California's pipeline and companies are expected to invest \$50 billion in new facilities, equipment and employees. At the event, life science leaders will present a strategic action plan to capture this massive investment in the State of California and will provide perspective on innovation and the challenges of developing new treatments and cures in the State. For more information, please visit the BayBio website at www.baybio.org.

About XDx

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary testing, the AlloMap® Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management.

Some of the AlloMap Molecular Expression Technology developed and implemented by

XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases affecting the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

XDx has several ongoing studies focused on FDA-approved AlloMap Molecular Expression Testing. The company anticipates results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial, a comparative efficacy clinical study designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared to endomyocardial biopsy, in early 2010.

###